Free Research Reports on These Medical Equipment Stocks -- Corindus Vascular Robotics, InspireMD, Second Sight Medical Products, and ReShape Lifesciences

NEW YORK, Dec. 13, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on CVRS, NSPR, EYES, and RSLS which is a click away at www.wallstequities.com/registration. WallStEquities.com is currently focused on the Medical Appliances and Equipment industry, which primarily offers equipment and devices that are designed for the diagnosis, monitoring, and treatment of patients in healthcare systems worldwide. Equities in this morning's lineup are: Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), InspireMD Inc. (NYSE AMER: NSPR), Second Sight Medical Products Inc. (NASDAQ: EYES), and ReShape Lifesciences Inc. (NASDAQ: RSLS). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: www.wallstequities.com/registration

Corindus Vascular Robotics

Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc.'s stock finished Tuesday's session 5.22% lower at $1.09 with a total trading volume of 463,077 shares. Over the last month and since the start of this year, the Company's shares have surged 27.95% and 56.07%, respectively. The stock is trading below its 50-day moving average by 5.57%. Moreover, shares of the Company, which designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures, have a Relative Strength Index (RSI) of 46.59.  

On December 01^st, 2017, Corindus Vascular Robotics announced that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath^® GRX Systems. In addition, and as part of the program launch, the Company will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions. Free Access to this morning's research report on CVRS at: www.wallstequities.com/registration/?symbol=CVRS

InspireMD

Shares in Tel Aviv, Israel headquartered InspireMD Inc. climbed 1.99%, ending yesterday's session at $0.13. A total volume of 3.48 million shares was traded, which was above their three months average volume of 2.46 million shares. The stock is trading 63.26% below its 50-day moving average. Moreover, shares of InspireMD, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 25.77. 

On December 04^th, 2017, InspireMD announced that it has signed Diverse Devices Pty Ltd as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production and Trading JSC as its exclusive distributor in Vietnam. Find your free research report NSPR at: www.wallstequities.com/registration/?symbol=NSPR

Second Sight Medical Products

On Tuesday, Sylmar, California headquartered Second Sight Medical Products Inc.'s stock skyrocketed 17.50%, to close the day at $2.35. A total volume of 3.98 million shares was traded, which was above their three months average volume of 580,870 shares. The Company's shares have advanced 99.15% in the last one month, 95.83% in the previous three months, and 19.29% on an YTD basis. The stock is trading 91.41% and 94.39% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the US, Italy, Germany, France, and Canada, have an RSI of 86.52. 

On December 05^th, 2017, Second Sight Medical Products announced market entry into Iran, implanting the first two patients with the Company's Argus^® II Retinal Prosthesis System. The implant was facilitated by the country's exclusive distribution partner, Arshia Gostar Darman Co. Ltd. Sign up today for the free research report on EYES at: www.wallstequities.com/registration/?symbol=EYES

ReShape Lifesciences

Shares in St. Paul, Minnesota headquartered ReShape Lifesciences Inc. ended the day 1.46% lower at $1.35. A total volume of 214,226 shares was traded. The stock is trading below its 50-day moving average by 23.18%. Furthermore, shares of ReShape Lifesciences, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 35.67. 

On December 04^th, 2017, ReShape Lifesciences announced that its ReShape Integrated Dual Balloon technology has been granted employee coverage through a supplemental coverage policy at a multinational telecommunications corporation that provides mobile telephone, fixed telephone, and broadband subscription television services. Wall St. Equities' research coverage also includes the downloadable free report on RSLS at: www.wallstequities.com/registration/?symbol=RSLS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities